DMP — Dermapharm Holding SE Balance Sheet
0.000.00%
- €2.44bn
- €3.22bn
- €1.16bn
Annual balance sheet for Dermapharm Holding SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 173 | 162 | 160 | 122 | 204 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 84.2 | 103 | 97.9 | 112 | 120 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 519 | 534 | 630 | 593 | 703 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 222 | 226 | 331 | 315 | 319 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,407 | 1,413 | 2,161 | 2,080 | 2,187 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 156 | 218 | 394 | 327 | 343 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 910 | 881 | 1,621 | 1,476 | 1,492 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 497 | 532 | 539 | 604 | 694 |
| Total Liabilities & Shareholders' Equity | 1,407 | 1,413 | 2,161 | 2,080 | 2,187 |
| Total Common Shares Outstanding |